Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

NHS funding

Reforms to Individual Patient Funding Request system in Wales approved

Patients in Wales will no longer have to prove they have “exceptional clinical circumstances” in order to access drugs that are not routinely available on the NHS.

From September 2017, patients will be entitled to access such drugs if they can show the drug will bring “significant clinical benefit” and that it represents “reasonable value for money”.

The changes follow a review of the Individual Patient Funding Request (IPFR) system, under which patients are entitled to make individual requests to specific health board panels for access to drugs not routinely available on the NHS.

The independent review, the findings of which were published in January 2017, found that the present system was confusing and that the commissioning arrangements were “inconsistent”, as was the whole IPFR process.

Social factors will no longer be considered as part of the decision-making process, according to the reforms, which were approved on 21 March 2017 by health secretary Vaughan Gething.

Vaughan Gething, health secretary in Wales

Source: Nick Treharne

Vaughan Gething says that the reforms to the IPFR system are “pragmatic” and will help health boards reach sensitive, and often complex, decisions

Ahead of a statement to the National Assembly to Wales, Gething said that the recommendations are “pragmatic” and will help health boards reach decisions which are often “sensitive” and “complex”.

“I am particularly pleased that the patient voice has centre stage in the report…,” he said. “I believe the recommendations… will have a positive impact on the IPFR process. It will make the system more easily understandable and less prone to being misused — something I’m sure the people of Wales will welcome.”

The changes were welcomed by Richard Greville, director of the Association of the British Pharmaceutical Industry Cymru Wales, who says patients would now have “level access to treatment based on clinical need”.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202491

Readers' comments (1)

  • Why should not patients in England .,...should have the same right to be treated with those drugs.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Vaughan Gething, health secretary in Wales

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.